24 July 2023 - New Brunswick lists Albrioza on its drug benefit formulary, becoming the fourth province to provide public ...
19 July 2023 - Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with British ...
11 July 2023 - In an out of session consideration, the PBAC has recommended changes to the restriction criteria and eligible ...
5 July 2023 - Report will be subject of New England CEPAC meeting in February 2024; draft scoping document open ...
5 July 2023 - Nearly 300 children with cystic fibrosis and two copies of the F508del mutation are now eligible ...
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, ...
28 June 2023 - Seeking inclusion of CV risk reduction indications in Europe. ...
27 June 2023 - Allecra Therapeutics announced today the submission of a new drug application to the US FDA for ...
27 June 2023 - Approval makes Xigduo XR the only once daily fixed-dose combination of an SGLT2 inhibitor and metformin ...
26 June 2023 - This is the first and only single tablet combination therapy to be submitted for review in Europe ...
23 June 2023 - Amylyx will seek re-examination of its conditional marketing authorisation application. ...
14 June 2023 - SMC has collaborated with NICE on Technology Appraisal, TA900: tixagevimab-cilgavimab for preventing COVID-19. ...
15 June 2023 - Amylyx will now work with federal, provincial, and territorial drug plans to ensure public coverage is available ...
14 June 2023 - Approval for Akeega is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision ...
31 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...